Activation of CD8+ T cells in vivo following reovirus delivery, and the negative correlation between CD8+ TEM cells and tumor burden (figure 2), suggested a potential role for T cells in reovirus efficacy; therefore, we sought to examine this using human CTL priming assays.6 As expected, reovirus treatment of human iDC increased expression of CD80, CD86 and HLA-DR on DC (online supplemental figure S7A),18 demonstrating its potential to support priming of adaptive MM-specific CTLs. The gene discussed is CD8A; the disease is Miyoshi myopathy.